Agilent Technologies Introduces Updated Designer Drug and Oral Fluid Compendiums, Plus Expanded Drug Compound Library for

  Agilent Technologies Introduces Updated Designer Drug and Oral Fluid
  Compendiums, Plus Expanded Drug Compound Library for Forensics and
  Toxicology

             Webinars to Highlight New Applications for LC/MS, MS

Business Wire

SANTA CLARA, Calif. -- February 4, 2013

Agilent Technologies Inc. (NYSE: A) today introduced new application
compendiums on designer drug testing and toxicology of oral fluids.

Also available is an expanded GC/MS Designer Drug Library. The only resource
of its kind, this searchable library includes designer stimulants that are
often marketed as “bath salts” as well as additional cannabinoid compounds.

In tandem with the release of these new resources, Agilent is sponsoring
monthly webinars featuring industry experts who will discuss new LC/MS and MS
applications for forensic detection and analysis of designer drugs and
metabolites.

“Designer drugs—especially bath salts—continue to make headlines across the
country,” said Tom Gluodenis, Agilent’s global marketing manager of Forensics
and Toxicology. “The important resources we’re introducing today, used in
collaboration with our specialized GC/MS laboratory technologies, provide
forensic practitioners, crime laboratories, and federal workplace drug-testing
programs with cost-effective, end-to-end solutions for designer drug screening
and analysis.”

Designer drugs are formulated to get around existing definitions of illicit
compounds. Once difficult to trace, these substances can now be quickly
identified and analyzed using Agilent’s GC/MS technologies.

Agilent’s expanded application compendium, “Identification of Synthetic
Cannabinoids in Herbal Incense Blends by GC/MS,” contains information on 45
cannabinoids and describes how to facilitate rapid screening and
identification of these marijuana-like compounds. A companion compendium,
“Analysis of Designer Stimulants by GC/MS,” describes the analysis of 30
stimulants.

Agilent developed these compendiums, and the expanded GC/MS Designer Drug
Library, in collaboration with NMS Labs.

Screening oral fluid is an accurate and effective alternative to screening
urine or blood. It provides many collection advantages, and samples can be
more easily analyzed using highly sensitive enzyme immunoassays and LC-MS/MS
instrumentation. Agilent’s updated oral fluid compendium, “Drugs and
Metabolites in Oral Fluid: Immunoassay Screening and LC/MS/MS Confirmation and
Quantification,” is a comprehensive treatise on the detection of drugs of
abuse in oral fluid, covering 100 drugs in 11 classes.

The compendium includes information on sample collection and preparation,
immunoassay screening and LC/QQQ confirmation. It also reflects changes to the
mandatory guidelines for Federal Workplace Drug Testing Programs, and contains
protocols for all the newly recommended Schedule II prescription medications.
Agilent developed the compendium in collaboration with Immunalysis Corp.

To download the application compendium “Drugs and Metabolites in Oral Fluid,”
visit Agilent’s Forensics & Toxicology website.

Webinar Series for Forensic Practitioners

Throughout the year, Agilent will sponsor a monthly online educational series
focusing on the analysis of designer drugs and drugs of abuse. Hosted by RTI
International’s online education service on www.ForensicEd.org, the webinars
listed below will also be available for replay following the live events.
Additional webinars will be announced at a later date.

Comprehensive Workflow for Screening and Confirmation of Drugs in Oral Fluids,
now accessible for replay at Forensic Science Education: Dr. Christine Moore
of Immunalysis Corp. discusses designer drug compendiums, oral fluids sample
collection, preparation, drug extraction, immunoassay screening and LC/QQQ
confirmation equipment.

LC/QQQ Screening for 300 Designer Drugs and Metabolites, Tuesday, Feb. 26 at 9
a.m. and 1 p.m. EST: Dr. Tony DiCaprio of Florida International University’s
Forensic Science Institute will describe current work focusing on the
development of LC-QQQ-MS/MS-based methods for rapid screening of designer
drugs in forensic analysis.

GC/MS and GC/QQQ Screening for 300 Designer Drugs and Metabolites, Thursday,
April 18 at 9 a.m. and 1 p.m. EST: Dr. Jose Almirall, also of Florida
International University’s Forensic Science Institute, will focus on the
expanded Designer Drug Library that FIU has developed in partnership with
Agilent; discussion will also focus on the entire workflow for effective and
rapid screening of designer drugs.

Webinar co-sponsor RTI International is the Center of Excellence for the
United States National Institute of Justice. The upcoming webinars are part of
RTI’s specialized forensic education service, which provides online forensic
science training and continuing education courses to practitioners in forensic
science, law enforcement, medico-legal death investigation and forensic
toxicology.

About NMS Labs

NMS Labs (www.nmslabs.com) based in Willow Grove, Pa., is the nation’s
premiere independent clinical toxicology and diagnostic laboratory, backed by
a comprehensive list of accreditations and a team of more than 200 scientific
staff. A national reference laboratory, it offers more than 2,500 assays that
test for commonly abused and therapeutic drugs, environmental agents, metals
and more.

About Immunalysis Corporation

Immunalysis Corporation (www.immunalysis.com) develops, manufactures and
markets immunoassay reagents for the screening of drugs of abuse and other
small molecules in a variety of biological matrices. The company draws upon
its expertise in organic chemistry, immunology, biochemistry, assay
development and quality control to supply immunoassay reagents and validated
automation options. This combination provides forensic toxicologists with
powerful complete drug screening solutions to meet the challenges demanded by
alternative matrices.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at www.agilent.com/go/news.

Contact:

Agilent Technologies Inc.
Susan Berg, +1-408-553-7093
susan_berg1@agilent.com
 
Press spacebar to pause and continue. Press esc to stop.